ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Janssen files EGFR-targeting antibody amivantamab with EMA
January 05, 2021Janssen, the pharmaceutical division of Johnson & Johnson, has submitted a marketing authorisation application to the European Medicines Agency (EMA) for approval of its epidermal growth factor receptor (EGFR)-targeting bispecific antibody amivantamab. -
Janssen Submits BLA for Metastatic Lung Cancer Treatment
December 24, 2020The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic ... -
Janssen eyes US approval for EGFR-targeting NSCLC therapy
December 08, 2020Janssen has submitted an application the US Food and Drug Administration (FDA) seeking approval for its non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations therapy amivantamab. -
Janssen Announces Phase 1 Results for Amivantamab for Advanced NSCLC
May 21, 2020The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the Phase 1 CHRYSALIS study.
Pharma Sources Insight January 2025
